Finerenone Trials Signal Broad CKD Expansion but Overlook Integration and Equity Gaps

Three large randomized controlled trials (RCTs) presented at the 2026 European Renal Association Congress demonstrate finerenone's consistent 24% reduction in kidney failure or CKD progression across 14,574 patients, extending benefits from diabetic to non-diabetic and glomerular disease populations. The FIND-CKD RCT (n=1,584 non-diabetic CKD patients) showed a 23% composite risk drop when added to standard care, while the JAMA subset analysis in glomerular diseases reported 26% progression reduction and 42% albuminuria drop at 12 months. The Lancet pooled analysis confirmed 20% lower heart failure hospitalization or CV death and 12% all-cause mortality benefit, independent of diabetes status or baseline eGFR. These phase III RCTs, though industry-sponsored by Bayer with potential conflicts via investigator funding, surpass prior observational data in rigor and scale. Mainstream coverage, such as the MedicalXpress report, underplays real-world impact: CKD's projected rise to the fifth-leading cause of premature death by 2040 affects 850 million globally, yet finerenone's hyperkalemia signal (low discontinuation rates notwithstanding) and lack of head-to-head data versus SGLT2 inhibitors like dapagliflozin (DAPA-CKD RCT, n=4,303) leave combination strategies unaddressed. Equity gaps in low-resource settings, where most non-diabetic CKD burden resides, and cost-effectiveness modeling remain absent, risking limited access despite foundational-therapy potential.